SCOTUS refuses to hear Eli Lilly patent win

The US Supreme Court has declined to review Eli Lilly’s patent infringement victory against Dr Reddy’s and Hospira.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circ affirms Eli Lilly victories over cancer drugs

13 August 2019 The US Court of Appeals for the Federal Circuit last week affirmed two findings that Dr Reddy’s and Hospira had infringed Eli Lilly’s cancer drug Alimta.

Big Pharma

Eli Lilly to acquire Dermira for $1.1 billion

16 January 2020 Global healthcare provider Eli Lilly has agreed to buy Dermira, a biopharmaceutical company, for $1.1 billion, giving it access to a late-stage atopic dermatitis drug and allowing it to challenge Sanofi’s already fully-licenced dupilumab.

More on this story

Americas

Fed Circ affirms Eli Lilly victories over cancer drugs

13 August 2019 The US Court of Appeals for the Federal Circuit last week affirmed two findings that Dr Reddy’s and Hospira had infringed Eli Lilly’s cancer drug Alimta.

Big Pharma

Eli Lilly to acquire Dermira for $1.1 billion

More on this story

Americas

Fed Circ affirms Eli Lilly victories over cancer drugs

13 August 2019 The US Court of Appeals for the Federal Circuit last week affirmed two findings that Dr Reddy’s and Hospira had infringed Eli Lilly’s cancer drug Alimta.

Big Pharma

Eli Lilly to acquire Dermira for $1.1 billion